450 related articles for article (PubMed ID: 15150302)
1. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Pegram MD; Konecny GE; O'Callaghan C; Beryt M; Pietras R; Slamon DJ
J Natl Cancer Inst; 2004 May; 96(10):739-49. PubMed ID: 15150302
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.
Konecny GE; Pegram MD
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):32-6. PubMed ID: 15685824
[TBL] [Abstract][Full Text] [Related]
3. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
Konecny G; Untch M; Slamon D; Beryt M; Kahlert S; Felber M; Langer E; Lude S; Hepp H; Pegram M
Breast Cancer Res Treat; 2001 Jun; 67(3):223-33. PubMed ID: 11561768
[TBL] [Abstract][Full Text] [Related]
4. New combinations with Herceptin in metastatic breast cancer.
Winer EP; Burstein HJ
Oncology; 2001; 61 Suppl 2():50-7. PubMed ID: 11694788
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
6. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
[TBL] [Abstract][Full Text] [Related]
7. Role of gemcitabine in the treatment of advanced and metastatic breast cancer.
Heinemann V
Oncology; 2003; 64(3):191-206. PubMed ID: 12697958
[TBL] [Abstract][Full Text] [Related]
8. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
[TBL] [Abstract][Full Text] [Related]
9. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines.
Merlin JL; Barberi-Heyob M; Bachmann N
Ann Oncol; 2002 Nov; 13(11):1743-8. PubMed ID: 12419746
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab and chemotherapeutics: drug interactions and synergies.
Pegram MD; Lopez A; Konecny G; Slamon DJ
Semin Oncol; 2000 Dec; 27(6 Suppl 11):21-5; discussion 92-100. PubMed ID: 11236023
[TBL] [Abstract][Full Text] [Related]
11. In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer.
Gwe Ahn S; Ah Lee S; Woo Lee H; Min Lee H; Jeong J
Jpn J Clin Oncol; 2014 Jul; 44(7):624-31. PubMed ID: 24803548
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
13. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Slamon D; Pegram M
Semin Oncol; 2001 Feb; 28(1 Suppl 3):13-9. PubMed ID: 11301370
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab/chemotherapy combinations in metastatic breast cancer.
Ligibel JA; Winer EP
Semin Oncol; 2002 Jun; 29(3 Suppl 11):38-43. PubMed ID: 12138396
[TBL] [Abstract][Full Text] [Related]
15. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
16. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
[TBL] [Abstract][Full Text] [Related]
17. In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines.
Budman DR; Calabro A
Breast Cancer Res Treat; 2002 Jul; 74(1):41-6. PubMed ID: 12150451
[TBL] [Abstract][Full Text] [Related]
18. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
[TBL] [Abstract][Full Text] [Related]
19. Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations.
Mueck AO; Seeger H; Wallwiener D; Huober J
Eur J Gynaecol Oncol; 2004; 25(6):699-701. PubMed ID: 15597845
[TBL] [Abstract][Full Text] [Related]
20. HERe-2 stay: the continuing importance of translational research in breast cancer.
Sledge GW
J Natl Cancer Inst; 2004 May; 96(10):725-7. PubMed ID: 15150294
[No Abstract] [Full Text] [Related]
[Next] [New Search]